ABBV heads into its May 8 Q1 earnings with the analyst community firmly in the bull camp — and quietly raising the bar.
The clearest signal ahead of the print is the strength of recent analyst upgrades. Morgan Stanley lifted its target to $278 from $270 last week, maintaining Overweight. Canaccord Genuity raised to $265 and Evercore ISI pushed to $236 on Monday. The consensus mean target of $250 implies roughly 20% upside from the current $208.16 price. That's not a cautious consensus — it's a street that has been steadily moving numbers higher into the release, with the EPS 12-month forward estimate ranking in the 98th percentile year-on-year. The stock has rebounded 5.5% over the past week, recovering much of a flat month.
The bull case rests on portfolio breadth. Immunology and oncology are the core growth engines, but the acquisitions of Allergan, Cerevel, and ImmunoGen have added meaningful diversification in neuroscience and oncology. Q1 revenue is expected to come in around $15 billion, up roughly 12% year-on-year, with EBITDA margins running near 45%. Analysts singled out Vraylar's life cycle management potential and a strong neuroscience pipeline as reasons to stay constructive. The bear angle is narrower but pointed: Humira biosimilar erosion remains an unresolved drag, and any miss on commercial execution — particularly on newer immunology assets — could test patience given the stock trades at approximately 13.9x trailing earnings, well off the frothy premium once attached to that franchise.
Short positioning tells a far less dramatic story. At 1.2% of the free float, short interest is modest — though it has climbed 15% over the past month, adding roughly 2.7 million shares. That's a move worth noting, not a signal of outright conviction from bears. Borrow availability is ample and cost to borrow remains negligible at 0.37%, up 36% on the week but still well below any level suggesting squeeze pressure. Options positioning is mildly defensive: the put/call ratio has edged to 1.10, slightly above its 20-day average of 1.07, near the top of its 52-week range. That's caution, not alarm. The ORTEX short score of 30.9 ranks in the 77th percentile of the universe — elevated relative to the stock's own history, but not screaming a one-sided trade.
Insider selling in late February — CEO Robert Michael and the CFO both filing sales at around $232 — is worth flagging as context, though the stock has since pulled back from those levels and the sales appear to have been spread across multiple executives simultaneously, suggesting routine compensation-related activity rather than a directional signal.
The May 8 print will test whether AbbVie's non-Humira portfolio is growing fast enough to justify a consensus that has been getting more ambitious, not less.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
